Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ILMN
+2.89 (1.72%)
After Hours: 170.58 0.00 (0.00%)
Mar 24, 5:45PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 167.82 - 171.98
52 week 119.37 - 186.88
Open 168.94
Vol / Avg. 874,067.00/926,618.00
Mkt cap 24.94B
P/E 54.57
Div/yield     -
EPS 3.13
Shares 146.30M
Beta 0.82
Inst. own 95%
Jan 31, 2017
Q4 2016 Illumina Inc Earnings Release (Estimated)
Jan 9, 2017
Illumina Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 9, 2017
Illumina Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '17) 2017
Net profit margin 17.36% 17.85%
Operating margin 23.09% 24.48%
EBITD margin - 29.68%
Return on average assets 10.14% 10.74%
Return on average equity 22.37% 22.87%
Employees 5,500 -
CDP Score - -


5200 Illumina Way
SAN DIEGO, CA 92122-4616
United States - Map
+1-858-2024500 (Phone)
+1-858-2024766 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Officers and directors

Jay T. Flatley Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Francis A. deSouza President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Sam Samad Chief Financial Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Marc A. Stapley Executive Vice President, Chief Administrative Officer
Age: 46
Bio & Compensation  - Reuters
Garret Hampton Ph.D. Executive Vice President - Clinical Genomics
Bio & Compensation  - Reuters
Omead Ostadan Executive Vice President - Operations, Products and Strategy
Age: 44
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Paula Dowdy Senior Vice President and General Manager
Bio & Compensation  - Reuters
Paul L. Bianchi Senior Vice President - Human Resources
Age: 54
Bio & Compensation  - Reuters